Citations

Showing 10 of 108162 citations.

Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels
Shelly, Shahar , Mills, John R. , Ζεκερίδου, Αναστασία , Pittock, Sean J. , Harper, C. Michel , Naddaf, Elie , Milone, Margherita , Mandrekar, Jay , Naddaf, Elie , Klein, Christopher J , Pittock, S J , Shahar, Shelly , Dubey, Divyanshu , McKeon, Andrew , Klein, Christopher J.

Mayo Clinic

Neurology | April 26, 2021 | Volume: 96 | Issue: 24 | Pages: No page available

10.1212/wnl.0000000000012050 | PMID 33903199 Get It

“What Matters to Me”: What pediatric stem cell transplant patients want their providers to know
McCarthy, Sarah , Tarquini, Sarah, Metcalf, Brittany, Pickard, Lucy, Greenzang, Katie A. , Mack, Jennifer W. , McCarthy, Sarah R. , McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Journal of Psychosocial Oncology | April 26, 2021 | Volume: 39 | Issue: 4 | Pages: 586-593

10.1080/07347332.2021.1906376 | PMID 33900895 Get It

Plasma membrane vesiculation in 3T3 and SV3T3 cells: II. factors affecting the process of vesiculation
Scott, Robert E., Maercklein, Peter B., Scott, Robert E.

Mayo Clinic

Journal of Cell Science | April 26, 2021 | Volume: 35 | Issue: 1 | Pages: 245-252

10.1242/jcs.35.1.245 | PMID 422673 Get It

ABSTRACT Plasma membrane vesicles are shed from monolayer cell cultures during incubation in low concentrations of formaldehyde and other sulphydryl blocking reagents. In both 3T3 and SV3T3 cells disulphide reducing agents, including dithiothreitol and mercaptoethanol, potentiate formaldehyde-induced vesiculation. Plasma membrane vesiculation is shown to be a temperature-dependent phenomenon which occurs optimally between 22 and 37 °C and at pH 7·0 to 7·5. Membrane shedding is an energy-dependent phenomenon, requiring monovalent and divalent cations and slightly hypertonic medium. Plasma membrane vesiculation is not affected by pretreatment of cells with inhibitors of protein synthesis, i.e. cycloheximide, nor by agents which disrupt the cytoskeleton.
Plasma membrane vesiculation in 3T3 and Sv3T3 cells: I. morphological and biochemical characterization
Scott, Robert E., Perkins, Roger, Zschunke, Michael A., Hoerl, Bryan J., Maercklein, Peter B., Scott, Robert E.

Mayo Clinic

Journal of Cell Science | April 26, 2021 | Volume: 35 | Issue: 1 | Pages: 229-243

10.1242/jcs.35.1.229 | PMID 370129 Get It

ABSTRACT 3T3 and SV3T3 mouse embryo cells and a variety of other monolayer cell lines can be induced to form and shed plasma membrane vesicles by exposure to sulphydryl blocking agents including formaldehyde and N-ethyl malemide. Morphological studies show that multiple vesicles are formed and released from individual cells and that the vesicle membrane is continuous with the plasma membrane of the cell. Vesicles measure from 0 ·1 to 15 μm in diameter and are free of detectable contamination with cytoplasmic membranes and organelles. Vesicles also show a 10-fold enrichment in the plasma membrane marker enzyme 5’nucleotidase and are devoid of detectable NADH-cytochrome C reductase and succinic dehydrogenase activity which are marker enzymes for endoplasmic reticulum and mitochondria, respectively. Vesicles have a high cholesterol: phospholipid ratio and show enrichment in sphingomyelin content. They contain receptors for Con A and WGA, approximately 20 size class polypeptides and intra-membranous particles. These results suggest that vesicles are derived from and have the general characteristics of plasma membranes.
Patient Release and Instructions for Lutetium Dotatate Radiopharmaceutical Therapy
Underwood, James Kyle, Sturchio, Glenn M., Arnold, Susan , Sturchio, Glenn

Mayo Clinic

Health Physics | April 26, 2021 | Volume: 121 | Issue: 2 | Pages: 160-165

10.1097/hp.0000000000001425 | PMID 33899756 Get It

Abstract Lutetium Dotatate radiopharmaceutical therapy (Lutathera) was approved by the United States Food and Drug Administration in 2018 and is used to treat somatostatin receptor positive neuroendocrine tumors. With all new radiopharmaceutical therapies, the radiation exposure to members of the public from the patient who received the therapy must be within regulatory limits and safe. If the patient will expose members of the public to too much radiation, the therapy must be performed on an inpatient basis. This paper shows that the administration of Lutathera can be done on an outpatient basis and provides safety and travel restrictions that should be communicated to the patient prior to leaving. The guidance presented herein serves as a basis for medical institutions looking to use Lutathera to treat patients.
Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
Terra, Simone , Roden, Anja C. , Yi, Eunhee S. , Aubry, Marie Christine, Boland, Jennifer M.

Mayo Clinic

American Journal of Clinical Pathology | April 26, 2021 | Volume: 157 | Issue: 1 | Pages: 33-39

10.1093/ajcp/aqab091 | PMID 34463336 Get It

Abstract Objectives Differentiating malignant pleural mesothelioma from benign reactive mesothelial processes can be quite challenging. Ancillary tests such as BRCA1-associated protein 1 (BAP1) immunohistochemistry and p16 fluorescence in situ hybridization (FISH) are helpful tools to aid in this distinction. Immunohistochemistry for methylthioadenosine phosphorylase (MTAP) has recently been proposed as an effective surrogate marker for p16 FISH and is an attractive alternative test due to shorter turnaround time. There are little data regarding the specificity of MTAP loss for mesothelioma or whether it may be useful to distinguish mesothelioma from the most common entity in the differential diagnosis, sarcomatoid carcinoma. Methods We studied well-characterized cases of sarcomatoid carcinoma (n = 34) and sarcomatoid mesothelioma (n = 62), which were stained for MTAP (clone 2G4) and BAP1 (clone C-4). Results Loss of MTAP expression was observed in 17 (50%) of 34 pulmonary sarcomatoid carcinomas; BAP1 expression was retained in all of the cases in which it was performed (n = 31). MTAP expression was lost in 38 (61%) of 62 sarcomatoid mesotheliomas; BAP1 was lost in 6 (10%) of 62. In the six cases with BAP1 loss, five also had loss of MTAP, while MTAP expression was retained in one. Conclusions Loss of MTAP expression by immunohistochemistry is common in pulmonary sarcomatoid carcinoma, as it is present in half of cases. This rate is similar to what is observed in sarcomatoid mesothelioma (61%). Therefore, this stain is not useful to distinguish between these two malignancies. MTAP loss is more common than BAP1 loss in the setting of sarcomatoid mesothelioma (61% vs 10%, respectively).
Association of Metformin With Volumetric Tumor Growth of Sporadic Vestibular Schwannomas
Armstrong, Michael , Lohse, Christine M. , Lees, Katherine A. , Carlson, Matthew L. , Armstrong, Michael F

Mayo Clinic

Otology & Neurotology | April 26, 2021 | Volume: 42 | Issue: 7 | Pages: 1081-1085

10.1097/mao.0000000000003149 | PMID 34260511 Get It

Objective: Recent research demonstrates a potential association between metformin use and reduced sporadic vestibular schwannoma (VS) growth in patients undergoing conservative observation. The current study was designed to elucidate the effect of metformin on tumor growth in sporadic VS using volumetric analyses. Study Design: Retrospective cohort. Setting: Tertiary referral center. Patients: Patients with sporadic VS who elected initial conservative treatment with at least two serial magnetic resonance imaging (MRI) scans were included. Interventions: Metformin use among patients with observed sporadic VS. Main Outcome Measures: Tumor growth, defined as an increase in volume of at least 20% from the initial MRI. Results: A total of 361 patients were evaluated. Thirty-four patients (9%) had a diagnosis of diabetes at baseline. Nineteen patients (5%) were taking metformin at the time of the initial MRI. Metformin use was not significantly associated with a reduced risk of volumetric tumor growth in a univariable analysis in all patients undergoing observation for VS (hazard ratio [HR] 0.75; 95% confidence intervals [CI] 0.40–1.42; p = 0.38) or within the diabetic subset (HR 0.79; 95% CI 0.34–1.83; p = 0.58). Additionally, diabetes status, insulin dependence, hemoglobin A1c value, and metformin dose were not significantly associated with volumetric tumor growth. Conclusion: Despite promising initial results in several previous studies, our data suggest that metformin use does not significantly reduce the risk of volumetric tumor growth in sporadic VS.
Reply: Antifungal Prophylaxis
Pennington, Kelly M. , Kennedy, Cassie C. , Kennedy, Cassie C , Razonable, Raymund R.

Mayo Clinic

Annals of the American Thoracic Society | April 26, 2021 | Volume: 18 | Issue: 10 | Pages: 1755-1756

10.1513/annalsats.202104-445le | PMID 33901414 Get It

Lymph node positivity and association with long‐term survival for different histologies of appendiceal cancer
Webb, Christopher , Pockaj, Barbara A. , Gray, Richard J. , Stucky, Chee‐Chee , Wasif, Nabil , Wasif, Nabil , Chang, Yu‐Hui

Mayo Clinic

Journal of Surgical Oncology | April 26, 2021 | Volume: 124 | Issue: 1 | Pages: 88-96

10.1002/jso.26493 | PMID 33902156 Get It

Abstract Background Appendiceal cancers represent a diverse group of malignancies with varying biological behavior. The significance of lymph node metastases in relation to long‐term survival and chemotherapy response is poorly defined. Methods The National Cancer Database was queried to find patients diagnosed with appendiceal cancer from 1998 to 2012. Kaplan–Meier curves and multivariable Cox regression analyses were used to study the association between lymph node status and overall survival. Stage IV patients were excluded. Results The rate of nodal positivity of the 9841 patients with known node status was: signet ring 47.4%, carcinoid 42.3%, nonmucinous adenocarcinoma 28.8%, goblet cell 21.9%, and mucinous adenocarcinoma 20.4%. Node‐positive patients had worse long‐term survival for all subtypes with the exception of carcinoid tumors ( p < 0.001). The strongest association was for signet cell and goblet cell. Adjuvant chemotherapy in node‐positive patients improved survival for mucinous, nonmucinous, and signet ring cell histology ( p < 0.01), but not for goblet cell. Conclusions Nodal involvement in patients with appendiceal cancer varies in incidence, association with adverse survival, and response to systemic therapy. Individualized treatment algorithms for the management of the subtypes of appendiceal cancer are needed.
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascu
Bulluck, Heerajnarain , Paradies, Valeria , Barbato, Emanuele , Baumbach, Andreas , Bøtker, Hans Erik , Caterina, Raffaele De , Cavallini, Claudio , Davidson, Sean M. , Feldman, Dmitriy N. , Gili, Sebastiano , Gyöngyösi, Mariann , Kunadian, Vijay , Ooi, Sze‐Yuan , Madonna, Rosalinda , Marber, Michael , Tarantini, Giuseppe , Birgelen, Clemens von , Zeitouni, Michel , Jaffe, Allan S. , Thygesen, Kristian , Hausenloy, Derek J. , De Caterina, Raffaele , Davidson, Sean M , Gili, Sebastiano , Gyöngyösi, Mariann , Kunadian, Vijay , Madonna, Rosalinda , Marber, Michael , Perrino, Cinzia , Sluijter, Joost P G , Toth, Gabor G , Van Laake, Linda W , Jaffe, Allan S. , Thygesen, Kristian , Hausenloy, Derek J , Capodanno, Davide , Ferdinandy, Péter , Mehran, Roxana , Ndrepepa, Gjin , Schüpke, Stefanie , Silvain, Johanne

Mayo Clinic

European Heart Journal | April 26, 2021 | Volume: 42 | Issue: 27 | Pages: 2630-2642

10.1093/eurheartj/ehab271 | PMID 34059914 Get It

Abstract A substantial number of chronic coronary syndrome (CCS) patients undergoing percutaneous coronary intervention (PCI) experience periprocedural myocardial injury or infarction. Accurate diagnosis of these PCI-related complications is required to guide further management given that their occurrence may be associated with increased risk of major adverse cardiac events (MACE). Due to lack of scientific data, the cut-off thresholds of post-PCI cardiac troponin (cTn) elevation used for defining periprocedural myocardial injury and infarction, have been selected based on expert consensus opinions, and their prognostic relevance remains unclear. In this Consensus Document from the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI), we recommend, whenever possible, the measurement of baseline (pre-PCI) cTn and post-PCI cTn values in all CCS patients undergoing PCI. We confirm the prognostic relevance of the post-PCI cTn elevation &gt;5× 99th percentile URL threshold used to define type 4a myocardial infarction (MI). In the absence of periprocedural angiographic flow-limiting complications or electrocardiogram (ECG) and imaging evidence of new myocardial ischaemia, we propose the same post-PCI cTn cut-off threshold (&gt;5× 99th percentile URL) be used to define prognostically relevant ‘major’ periprocedural myocardial injury. As both type 4a MI and major periprocedural myocardial injury are strong independent predictors of all-cause mortality at 1 year post-PCI, they may be used as quality metrics and surrogate endpoints for clinical trials. Further research is needed to evaluate treatment strategies for reducing the risk of major periprocedural myocardial injury, type 4a MI, and MACE in CCS patients undergoing PCI.